Neuraltus Pharmaceuticals, Inc.: Series B $9.6M

Posted in I - Series B, Q - 4Q11, R - WEST, X - ALS, X - Alzheimer's, X - Lysosomal Storage, X - Multiple Sclerosis, X - Neuro Degenerative, X - Parkinson's, XX - CA

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Jun

2010

FoldRx Pharmaceutials, Inc.: Series C $29M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Cardiology, X - Neuro Degenerative, X - Protein Folding, XX - MA

FoldRx Pharmaceuticals (Cambridge) a clinical-stage small molecule company focused on protein misfolding and aggregation in transthyretin amyloid polyneuropathy and other neurodegenerative and cardiovascular diseases, closed a $29M Series C financing. Participants include Novo Ventures, Morgenthaler Ventures, HealthCare Ventures, Fidelity Biosciences, TPG Biotech, Alta Partners and Novartis Venture Funds.

to top of page...